Results from CONTESSA 2: A Multinational, Multicenter, Phase 2 Study of Tesetaxel (T) Plus a Reduced Dose of Capecitabine (C) in Patients (pts) with Hormone Receptor + (HR+), HER2- Metastatic Breast Cancer (MBC) Not Previously Treated with a Taxane.
Journal of clinical oncology（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined